New mutation linked to non-Hodgkin's lymphoma

Some patients with non-Hodgkin lymphoma (NHL) -- a cancer of B cells -- harbor a particular mutation in the gene encoding the receptor for B cell activating factor (BAFF), according to a paper published online on November 1 in the Journal of Experimental Medicine. BAFF, a soluble protein needed for B cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.

This BAFF-R mutation, identified by a team led by Anne Novak and Gail Bishop, generates a receptor that transmits stronger than normal signals, thus boosting function.

Although present in fewer than 10% of the tumors analyzed in the study, this mutation provides further evidence of the importance of BAFF signaling in this dangerous malignancy.


Explore further

Researchers identify factor boosting leukemia's aggressiveness

More information: Hildebrand, J.M., et al. 2010. J. Exp. Med. doi:10.1084/jem.20100857
Citation: New mutation linked to non-Hodgkin's lymphoma (2010, November 1) retrieved 5 August 2021 from https://medicalxpress.com/news/2010-11-mutation-linked-non-hodgkin-lymphoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments